Skip to content

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01395862
Enrollment
1001
Registered
2011-07-18
Start date
2007-11-30
Completion date
2012-09-30
Last updated
2013-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Disorders

Brief summary

The purpose of this study is to detect adverse drug reactions for long-term use (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients who are treated with fluticasone propionate/salmeterol xinafoate.

Interventions

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Must use fluticasone and salmeterol for the first time * Must use fluticasone and salmeterol for long-term

Exclusion criteria

* Patients with hypersensitivity to salmeterol and fluticasone * Patients with infection which salmeterol and fluticasone is not effective * Patients with deep mycosis

Design outcomes

Primary

MeasureTime frame
The number of incidence of adverse events in Japanese asthma patients treated with fluticasone and salmeterol for long-term1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026